Home
/
Protalix BioTherapeutics, Inc.
/
Financials
/
Quarterly
Protalix BioTherapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Protalix BioTherapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$17.85M
Nov 13, 2025
Q2
2025
Jun 30, 2025
$15.66M
Aug 14, 2025
Q1
2025
Mar 31, 2025
$10.11M
May 9, 2025
Q3
2025
Sep 30, 2024
$17.96M
Nov 13, 2025
Q2
2025
Jun 30, 2024
$13.47M
Aug 14, 2025
Q1
2025
Mar 31, 2024
$3.75M
May 9, 2025
Q3
2024
Sep 30, 2023
$10.35M
Nov 14, 2024
Q2
2024
Jun 30, 2023
$35.08M
Aug 14, 2024
Q1
2024
Mar 31, 2023
$9.59M
May 10, 2024
Q3
2023
Sep 30, 2022
$14.18M
Nov 6, 2023
Q2
2023
Jun 30, 2022
$8.75M
Aug 7, 2023
Q1
2023
Mar 31, 2022
$16.09M
May 4, 2023
Q3
2022
Sep 30, 2021
$12.05M
Nov 14, 2022
Q2
2022
Jun 30, 2021
$6.43M
Aug 15, 2022
Q1
2022
Mar 31, 2021
$11.32M
May 16, 2022
Q3
2021
Sep 30, 2020
$10.79M
Nov 15, 2021
Q2
2021
Jun 30, 2020
$10.97M
Aug 16, 2021
Q1
2021
Mar 31, 2020
$21.65M
May 14, 2021
Q3
2020
Sep 30, 2019
$14.25M
Oct 29, 2020
Q2
2020
Jun 30, 2019
$12.25M
Aug 10, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$2.36M
Nov 13, 2025
Q2
2025
Jun 30, 2025
$164.0K
Aug 14, 2025
Q1
2025
Mar 31, 2025
($3.62M)
May 9, 2025
Q3
2025
Sep 30, 2024
$3.24M
Nov 13, 2025
Q2
2025
Jun 30, 2024
($2.20M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($4.60M)
May 9, 2025
Q3
2024
Sep 30, 2023
($1.85M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
$19.34M
Aug 14, 2024
Q1
2024
Mar 31, 2023
($3.13M)
May 10, 2024
Q3
2023
Sep 30, 2022
($3.57M)
Nov 6, 2023
Q2
2023
Jun 30, 2022
($5.33M)
Aug 7, 2023
Q1
2023
Mar 31, 2022
($2.29M)
May 4, 2023
Q3
2022
Sep 30, 2021
($4.20M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($11.24M)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($5.48M)
May 16, 2022
Q3
2021
Sep 30, 2020
($4.44M)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($4.15M)
Aug 16, 2021
Q1
2021
Mar 31, 2020
$1.67M
May 14, 2021
Q3
2020
Sep 30, 2019
($3.56M)
Oct 29, 2020
Q2
2020
Jun 30, 2019
($7.74M)
Aug 10, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$2.13M
Nov 13, 2025
Q2
2025
Jun 30, 2025
$1.17M
Aug 14, 2025
Q1
2025
Mar 31, 2025
($4.15M)
May 9, 2025
Q3
2025
Sep 30, 2024
$3.99M
Nov 13, 2025
Q2
2025
Jun 30, 2024
($2.43M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($4.86M)
May 9, 2025
Q3
2024
Sep 30, 2023
($1.89M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
$20.42M
Aug 14, 2024
Q1
2024
Mar 31, 2023
($2.46M)
May 10, 2024
Q3
2023
Sep 30, 2022
($3.13M)
Nov 6, 2023
Q2
2023
Jun 30, 2022
($5.52M)
Aug 7, 2023
Q1
2023
Mar 31, 2022
($1.87M)
May 4, 2023
Q3
2022
Sep 30, 2021
($1.89M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($9.17M)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($3.71M)
May 16, 2022
Q3
2021
Sep 30, 2020
($2.58M)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($2.24M)
Aug 16, 2021
Q1
2021
Mar 31, 2020
$4.69M
May 14, 2021
Q3
2020
Sep 30, 2019
($1.54M)
Oct 29, 2020
Q2
2020
Jun 30, 2019
($5.84M)
Aug 10, 2020